Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-08
2011-03-08
Eyler, Yvonne L (Department: 1619)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S960000
Reexamination Certificate
active
07902208
ABSTRACT:
A method of treating and/or preventing allergic and inflammatory conditions of the skin or upper and lower airway passages, e.g. seasonal allergic rhinitis, perennial allergic rhinitis, or chronic idopathic urticaria, in a human more 12 years old, by administering an amount of desloratadine, e.g. 2×2.5 mg or 5 mg/day for a time sufficient to produce a geometric mean steady state maximum plasma concentration of desloratadine in the range of about 2.90 ng/mL to about 4.54 ng/mL, or a arithmetic mean steady state maximum plasma concentration of desloratadine in the range of about 3.2 ng/mL to about 5.0 ng/mL is disclosed.
REFERENCES:
patent: 3536809 (1970-10-01), Applezweig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 3940485 (1976-02-01), Levinson et al.
patent: 4008796 (1977-02-01), Aylon et al.
patent: 4282233 (1981-08-01), Vilani
patent: 4371516 (1983-02-01), Gregory et al.
patent: 4552899 (1985-11-01), Sunshine et al.
patent: 4659716 (1987-04-01), Villani et al.
patent: 4731447 (1988-03-01), Schumacher et al.
patent: 4777170 (1988-10-01), Heinrich
patent: 4783465 (1988-11-01), Sunshine et al.
patent: 4804666 (1989-02-01), Piwinski et al.
patent: 4863931 (1989-09-01), Schumacher et al.
patent: 4906647 (1990-03-01), Kouchiwa et al.
patent: 4990535 (1991-02-01), Cho et al.
patent: 5019591 (1991-05-01), Gardner et al.
patent: 5089496 (1992-02-01), Piwinski et al.
patent: 5100675 (1992-03-01), Cho et al.
patent: 5314697 (1994-05-01), Kwan et al.
patent: 5407941 (1995-04-01), Carceller et al.
patent: 5476856 (1995-12-01), Carceller et al.
patent: 5502080 (1996-03-01), Hitzig
patent: 5595997 (1997-01-01), Aberg et al.
patent: 5698558 (1997-12-01), Gray
patent: 5731319 (1998-03-01), Aberg et al.
patent: 5839430 (1998-11-01), Cama
patent: 5900421 (1999-05-01), Handley et al.
patent: 5939426 (1999-08-01), McCullough
patent: 5962464 (1999-10-01), Handley et al.
patent: 6051585 (2000-04-01), Weinstein et al.
patent: 6054463 (2000-04-01), Handley et al.
patent: 6100274 (2000-08-01), Kou
patent: 6114346 (2000-09-01), Harris et al.
patent: 6132758 (2000-10-01), Munayyer et al.
patent: 6265414 (2001-07-01), Harris et al.
patent: 6270796 (2001-08-01), Weinstein
patent: 6423721 (2002-07-01), Harris et al.
patent: 6432972 (2002-08-01), Salmun et al.
patent: 6506767 (2003-01-01), Schumacher et al.
patent: 6514520 (2003-02-01), Munayyer et al.
patent: 6521254 (2003-02-01), Weinstein et al.
patent: 6599913 (2003-07-01), Johnson et al.
patent: 6709676 (2004-03-01), Cho
patent: 6979463 (2005-12-01), Kou
patent: 7405223 (2008-07-01), Affrime et al.
patent: 2003/0004179 (2003-01-01), Affrime et al.
patent: 0 264 259 (1988-04-01), None
patent: 0 288 640 (1988-11-01), None
patent: 0 396 404 (1990-11-01), None
patent: 0 577 957 (1994-01-01), None
patent: WO 85/03707 (1985-08-01), None
patent: WO-92/00293 (1992-01-01), None
patent: WO-92/11034 (1992-07-01), None
patent: WO-92/20377 (1992-11-01), None
patent: WO-96/16641 (1996-06-01), None
patent: WO-96/20708 (1996-07-01), None
patent: WO-98/34614 (1998-08-01), None
patent: WO 99/32125 (1999-07-01), None
patent: WO-00/02560 (2000-01-01), None
patent: WO-01/21161 (2001-03-01), None
patent: WO-01/21162 (2001-03-01), None
patent: WO-01/45668 (2001-06-01), None
patent: WO-01/45676 (2001-06-01), None
patent: WO-01/45688 (2001-06-01), None
Goodman and Gilman's, The Pharmacologic Basis of Therapeutics, Ninth Edition, McGraw-Hill, New York, (1996), Chapter 50, pp. 1191-1193.
DiPiro et al., Pharmacotherapy, A Pathophysiologic Approach, New York, (1989), Chapter 65, pp. 945-953.
Anderson, et al., “Adverse drug interactions clinically important for the dermatologist,” Arch Dermatol, Apr. 1995, vol. 131, pp. 468-473.
Babe, et al., “Histamine, Bradykinn, and their Antagonists,” in the Pharmacological Basis of Therapeutics (9th Edition), 1996, The McGraw-Hill Co. Inc., pp. 581-599.
Barnett, et al., “Pharmacology of Non-Sedating H 1 Antihistamines,” New Perspectives in Histamine Research, 1991, Birkhauser Vertag Bassel, pp. 181-196.
Berge, et al., “Pharmaceutical Salts,” J. of Pharm. Sciences, Jan. 1997, vol. 66, No. 1, pp. 1-19.
Berthon, et al., “In Vitro inhibition, by loratadine and descarboxyethoxyloratadine, of histamine release from human basophils, and of histamine release and intracellular calcuim fluxes in rat basophilic leukemia cells (RBL-2H3),” Biochem. Pharm., 1994, vol. 47, No. 5, pp. 789-794.
Blaug, et al., “Interaction of dextroamphetamine sulfate with spray-dried lactose,” J. of Pharm. Sciences, Nov. 1972, vol. 61, No. 11, pp. 1770-1775.
Brandes, et al., “Enhanced cancer growth in mice administered daily human-equivalent doses of some H1-antihistamines: predictive in vitro correlates,” J. of the National Cancel Inst., May 18, 1994, vol. 86, No. 10, pp. 770-775.
Brandes, et al., “Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses,” Cancer Research, Jul. 1, 1992, vol. 52, pp. 3796-3800.
Brion, et al., “Evaluation of the antimuscarinic activity of atropine, terfenadine and mequitazine in healthy volunteers,” Br. J. Clin. Pharmac. 1988, vol. 25, pp. 27-32.
Carmeliet, “Voltage- and Time-Dependent Block of the Delayed K+ Current in Cardiac Myocytes by Dofetilide,” The J. of Pharm. And Experimental Therapeutics, 1992, vol. 262, No. 2, pp. 809-817.
Castello, et al., “Discoloration of tablets containing amines and lactose,” J. of Pharm. Sciences, Feb. 1962, vol. 51, No. 2, pp. 106-108.
Cheung, et al., “Investigation of anti-motion sickness drugs in the squirrel monkey,” J. Clin. Pharmacol, 1992, vol. No. 32, pp. 163-175.
Clissold, et al., “Loratadine: A preliminary review of its pharmacodynamic properties and therapeutic efficacy,” Drugs, 1989, vol. 37, pp. 42-57.
Cooke, “Glycopyrrolate in bladder dysfunction,” SA Medical Journal, Jan. 1, 1983, p. 3.
Craft, “Torsade de pointes after astemizole overdose,” Br. Medical Journal, 1986, vol. 292, p. 660.
Dorje, et al., “Antagonist Binding Profiles of Five Cloned Human Muscarinic Receptor Subtypes,” The J. of Pharm. And Experimental Therapeutics, 1991, vol. 256, pp. 727-733.
Drug Facts and Comparisons, 1998 Ed., Facts and Comparisons, St. Louis, Missouri, p. 2832.
Ebert, “Soft elastic gelatin capsules: a unique dosage form,” Pharmaceutical Technology, 1977, pp. 44-50.
Gengo, “Dilemma: Antihistamine selection: Use vs. Side effects,” U.S. Pharmacist, Nov. 1990, pp. 59-92.
Hartauer, et al., A Comparison of Diffuse Reflectance FT-IR Spectroscopy and DSC in the Characterization of a Drug-Excipient Interaction, “Drug Development and industrial Pharmacy,” 1991, vol. 17, No. 4, pp. 617-630.
Herzog, et al., Urinary Incontinence: medical and Psychosocial Aspects, Annual Review of Gerontology and Geriatrics, 1989, vol. 9, pp. 74-119.
Hilbert, et al., “Pharmacokinetics and Dose Proportionality of Loratadine,” J. Clin. Pharmacol., 1987, vol. 27, pp. 694-698.
Housely, et al., “Histamine and related substances influence neurotransmission in the semicircular canal,” Hearing Research, May 1, 1988, Vo. 35, pp. 87-97.
Jankowski, et al., “Effect of Terfenadine on Nnasal Provocation,” Int. Arch. Allergy Immunolog., 1993, vol. 101, pp. 311-317.
Kaliner, “Nonsedating Antihistamines: Pharmacology, Clinical Efficacy and Adverse Effects,” American Family Physician, Mar. 1992, vol. 45, No. 3, pp. 1337-1342.
Kleine-Tebbe, et al., “Inhibition of IgE- and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H1-antagonist, desethoxycarbonyl-loratadine,” J. Allergy Clin. Immunol., 1994, vol. 93, pp. 494-500.
Knowles, “Astemizole and Terfenadine-Induced Cardiovascular Effects,” The Canadian J. of Hospital Pharmacy, Feb. 1992, Vo
Affrime Melton B.
Banfield Christopher R.
Gupta Samir K.
Padhi Desmond
Eyler Yvonne L
Jacobsen Barry H.
Jagoe Donna
Schering Corporation
LandOfFree
Treating allergic and inflammatory conditions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treating allergic and inflammatory conditions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating allergic and inflammatory conditions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2646296